Debra E Bramblett

Dr. Debra E Bramblett


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
HSHayle Scanlan
Hayle Scanlan
ZCZachary Coffman
Zachary Coffman
JBJeffrey Bettencourt
Jeffrey Bettencourt
TSTimothy Shipley
Timothy Shipley
DBDebra E Bramblett
Debra E Bramblett
The need for efficacious and non-toxic cancer therapies is paramount. Oncolytic viruses (OVs) are showing great promise and are introducing new possibilities in cancer treatment with their ability to selectively infect tumor cells and trigger antitumor immune responses. Herpes Simplex Virus 1 (HSV-1) is a commonly selected OV candidate due to its large genome, relative safety profile, and ability to infect a variety of cell types. Talimogene laherparevec (T-VEC) is an HSV-1-derived OV variant and the first and only OV therapy currently approved for clinical use by the United States Food and Drug Administration (FDA). This review provides a concise description of HSV-1 as an OV candidate and the genomic organization of T-VEC. Furthermore, this review focuses on the advantages and limitations in the use of T-VEC compared to other HSV-1 OV variants currently in clinical trials. In addition, approaches for future directions of HSV-1 OVs as cancer therapy is discussed.

SBSimran D Bhakta
Simran D Bhakta
TPTyler S. Peters
Tyler S. Peters
AMAlessandra Merenna
Alessandra Merenna
DBDebra E Bramblett
Debra E Bramblett
NM averages 450 new cases of melanoma annually. Promotoras are community health workers in NM that provide health education and resources to the community. The project aims to determine if promotora education can improve the recognition of suspicious lesions, encouraging community members to seek care. Current literature focuses on the self-reported confidence of CHWs in recognizing skin cancer. A total of 54 promotoras were sampled through a Qualtrics quiz asking whether skin lesion photos are suspicious. Participants were also asked to rate their confidence in recognizing a suspicious skin lesion and comfort in addressing it from 1 to 5. Participants then read an educational flyer about the “ABCDEs” of melanoma before repeating the quiz/ratings. Wilcoxon signed-rank testing revealed significant increases in quiz scores (W = 220.5, p = 0.045), confidence (W = 44.0, p < 0.001), and comfort (W = 8.5, p < 0.001). Promotoras could be an additional line of defense against melanoma, helping save lives. Healthcare personnel with limited skin lesion knowledge could be an ideal future population for education.